Highlights

• SUVEN shares declined sharply after a strong multi-week rally.
• The stock witnessed profit booking near recent swing highs around ₹290.00.
• RSI cooled significantly, indicating weakening short-term momentum.

Overview

Suven Life Sciences (NSE: SUVEN) emerged among the top losers on June 5, with the stock falling 7.47% to ₹246.90. The decline follows a powerful rally that had lifted the stock from around ₹130.00 in March to nearly ₹290.00 in recent sessions. While the broader medium-term structure remains positive, traders appeared to book profits after the sharp advance, resulting in a notable pullback.

Fundamental View

The company's latest quarterly performance remained under pressure. For the quarter ended March 2026, Suven Life Sciences reported total income of ₹829.79 lakh and a net loss of ₹4,559.55 lakh. Earnings per share stood at negative ₹2.02. The company has remained loss-making over recent quarters, which may have encouraged investors to lock in gains after the stock's substantial rally.

Technical View

SUVEN closed at ₹246.90, remaining above its 50-day SMA of ₹210.76 despite the sharp decline. The stock had been in a strong uptrend since April, forming a sequence of higher highs and higher lows. However, the latest session saw a decisive bearish candle after rejection near the ₹290.00 zone. The pullback suggests momentum has moderated following the recent surge, although the stock continues to trade above its key moving average.

Momentum Indicator

The 14-day RSI dropped to 51.44 from elevated levels seen during the rally. This decline reflects fading short-term momentum and indicates that bullish strength has cooled considerably. While the RSI remains above the neutral 50 level, traders may monitor whether momentum stabilizes near current levels.

Key Technical Levels

The stock is approaching an important support zone near ₹240.00, which coincides with the recent breakout region. A further decline could bring ₹225.00 into focus as the next support area. On the upside, resistance is visible near ₹272.10, the session high, while a stronger recovery would require the stock to reclaim the ₹290.00 zone where recent selling pressure emerged.

Risks to Watch

• Continued profit booking after the recent rally.
• Weak quarterly earnings performance.
• Failure to hold above the ₹240.00 support zone.
• Rising volatility near recent swing highs.

Summary

Suven Life Sciences came under pressure as traders booked profits following an extended rally that had more than doubled the stock from its March lows. Although the broader trend remains constructive with the price trading above its 50-day SMA of ₹210.76, weakening RSI momentum and recent rejection near ₹290.00 have increased near-term caution. The ability to hold above the ₹240.00 support area may determine the stock's next directional move.

FAQs

Why did SUVEN stock fall today?

The stock witnessed profit booking after a sharp multi-week rally and faced resistance near recent highs.

Is the broader trend still positive?

Yes, SUVEN continues to trade above its 50-day SMA of ₹210.76 despite the latest correction.

What levels should traders watch?

Support is seen near ₹240.00 and ₹225.00, while resistance is located around ₹272.10 and ₹290.00.